HDM1005
Asset
Long-acting dual GLP-1 and GIP receptor agonist promoting weight loss and improving glycemic control.
- Stage
- Phase 2
- Modality
- Peptide
- Target
- GLP1R
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Obesity
Phase 2, doi.org, 5 Jun 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.